Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vanitha Sekar

Showing results (1-10 of 23) with videos related to

Pageof 3
Sort By:
Therapeutic Innovation & Regulatory Science|February 10, 2026
Advancing Biomarker Qualification: FDA Perspective on Efficiency, Surrogate Endpoints, and Future DirectionsVanitha Sekar, Jeffrey Siegel
Clinical and Translational Science|October 2, 2025
Use of Biomarkers in Drug Development for Regulatory PurposesRobert N Schuck, Vanitha Sekar
Antiviral Therapy|April 9, 2008
Darunavir: pharmacokinetics and drug interactionsDavid Back, Vanitha Sekar, Richard M W Hoetelmans
The Journal of Antimicrobial Chemotherapy|May 26, 2010
Suboptimal adherence to darunavir/ritonavir has minimal effect on efficacy compared with lopinavir/ritonavir in treatment-naive, HIV-infected patients: 96 week ARTEMIS dataMark Nelson, Pierre-Marie Girard, Ralph Demasi, et al.
Journal of Clinical Pharmacology|April 28, 2010
Pharmacokinetic interactions between darunavir/ritonavir and opioid maintenance therapy using methadone or buprenorphine/naloxoneVanitha Sekar, Frank Tomaka, Eric Lefebvre, et al.
British Journal of Clinical Pharmacology|August 8, 2009
Pharmacokinetic interaction between nevirapine and darunavir with low-dose ritonavir in HIV-1-infected patientsVanitha Sekar, Eric Lefebvre, Kris Mariën, et al.
AIDS Research and Treatment|April 27, 2012
Pharmacokinetics and Pharmacodynamics of Darunavir and Etravirine in HIV-1-Infected, Treatment-Experienced Patients in the Gender, Race, and Clinical Experience (GRACE) TrialThomas Kakuda, Vanitha Sekar, Peter Vis, et al.
Clinical Pharmacokinetics|April 14, 2010
Pharmacokinetics of multiple-dose darunavir in combination with low-dose ritonavir in individuals with mild-to-moderate hepatic impairmentVanitha Sekar, Sabrina Spinosa-Guzman, Els De Paepe, et al.
Intervirology|March 4, 2010
Pharmacokinetic interaction between indinavir and darunavir with low-dose ritonavir in healthy volunteersVanitha Sekar, Eric Lefebvre, Tine De Marez, et al.
Antimicrobial Agents and Chemotherapy|July 28, 2010
Pharmacokinetics of darunavir/ritonavir and rifabutin coadministered in HIV-negative healthy volunteersVanitha Sekar, Ludo Lavreys, Tom Van de Casteele, et al.
Pageof 3

Showing results (1-10 of 23) with videos related to

Sort By:
Pageof 3
Therapeutic Innovation & Regulatory Science|February 10, 2026
Advancing Biomarker Qualification: FDA Perspective on Efficiency, Surrogate Endpoints, and Future DirectionsVanitha Sekar, Jeffrey Siegel
Clinical and Translational Science|October 2, 2025
Use of Biomarkers in Drug Development for Regulatory PurposesRobert N Schuck, Vanitha Sekar
Antiviral Therapy|April 9, 2008
Darunavir: pharmacokinetics and drug interactionsDavid Back, Vanitha Sekar, Richard M W Hoetelmans
The Journal of Antimicrobial Chemotherapy|May 26, 2010
Suboptimal adherence to darunavir/ritonavir has minimal effect on efficacy compared with lopinavir/ritonavir in treatment-naive, HIV-infected patients: 96 week ARTEMIS dataMark Nelson, Pierre-Marie Girard, Ralph Demasi, et al.
Journal of Clinical Pharmacology|April 28, 2010
Pharmacokinetic interactions between darunavir/ritonavir and opioid maintenance therapy using methadone or buprenorphine/naloxoneVanitha Sekar, Frank Tomaka, Eric Lefebvre, et al.
British Journal of Clinical Pharmacology|August 8, 2009
Pharmacokinetic interaction between nevirapine and darunavir with low-dose ritonavir in HIV-1-infected patientsVanitha Sekar, Eric Lefebvre, Kris Mariën, et al.
AIDS Research and Treatment|April 27, 2012
Pharmacokinetics and Pharmacodynamics of Darunavir and Etravirine in HIV-1-Infected, Treatment-Experienced Patients in the Gender, Race, and Clinical Experience (GRACE) TrialThomas Kakuda, Vanitha Sekar, Peter Vis, et al.
Clinical Pharmacokinetics|April 14, 2010
Pharmacokinetics of multiple-dose darunavir in combination with low-dose ritonavir in individuals with mild-to-moderate hepatic impairmentVanitha Sekar, Sabrina Spinosa-Guzman, Els De Paepe, et al.
Intervirology|March 4, 2010
Pharmacokinetic interaction between indinavir and darunavir with low-dose ritonavir in healthy volunteersVanitha Sekar, Eric Lefebvre, Tine De Marez, et al.
Antimicrobial Agents and Chemotherapy|July 28, 2010
Pharmacokinetics of darunavir/ritonavir and rifabutin coadministered in HIV-negative healthy volunteersVanitha Sekar, Ludo Lavreys, Tom Van de Casteele, et al.
Pageof 3